The biopharma world is here. Get the industry’s most comprehensive daily news reports at https://teapawt.net/t.co/qpcDlbaOSx
Global
Joined August 2015
- Tweets51K
- Following80
- Followers32.8K
- Likes4.5K
Moderna posted its first profitable quarter in two years on international Covid vaccine sales, as its cancer vaccine spending grows. endpoints.news/moderna-notch…
Sarepta won't resume enrollment in Elevidys' confirmatory Phase 3 trial, on hold since a second patient death last year. endpoints.news/sarepta-quits…
The Trump administration pointed to national security to push tariffs and protectionist policies. But leaning into that means “everything is going to get more expensive,” said Nick Shipley, founder of Cronus Consulting, on Post-Hoc Live. Will the Democrats’ focus on affordability mean moving away from that approach, with implications for COINS and other China policy? Catch up on our post-midterm conversation: youtube.com/live/ghjQxZj1bWQ
Novartis disclosed seven new tumor cases in Zolgensma patients and says two may be linked to the gene therapy. endpoints.news/seven-new-tum…
In this week's Peer Review: Novo and Pfizer make CFO hires, and Alnylam's chief commercial officer exits as struggles continue. endpoints.news/novo-pfizer-m…
Preeclampsia nearly took Emily Chaddock's life and her baby's. Drugs to prevent it are finally on the horizon. endpoints.news/preeclampsia-…
Merck's MASH drug from Hanmi cleared a Phase 2b, with 63% of patients on the best dose reaching resolution vs. 13% on placebo. endpoints.news/aasld26-merck…
Caldera and Evommune each paid $30M upfront to license autoimmune drugs from Chinese biotechs. endpoints.news/caldera-evomm…
Kamau is reviving Graphite Bio's sickle cell gene editing therapy, and all three patients in its first cohort are transfusion-free. endpoints.news/kamau-shares-…
Oxford spinout Alethio raised $90M to advance its antibody for a rare blood cancer, about a year after emerging from stealth. endpoints.news/alethio-clinc…
T-Therapeutics raised $133M for cancer and autoimmune TCRs, adding J&J, Merck KGaA and Lilly as backers. endpoints.news/t-therapeutic…
CVS is breaking up, splitting its retail pharmacies from Aetna and Caremark, sending shares down 12%. endpoints.news/cvs-to-break-…
Boehringer Ingelheim is paying $358M upfront for six preclinical ADCs and T cell engagers from China's Sino, in a deal that could top $7B. endpoints.news/boehringer-in…
The US midterm elections and biopharma teapawt.net/i/broadcasts/2gqWlyAWQ…
🎙️ Live today at 1:30 pm ET: @ArmstrongDrew, @maxonwifi and Nick Shipley unpack what the midterms mean for drug pricing, MFN deals and the FDA. endpoints.news/post-hoc-live…
Novo won't launch CagriSema in Europe for "a couple of years" because of extra EMA trial requirements, its outgoing CFO told Endpoints. endpoints.news/novo-wont-lau…
AbbVie is paying $100M upfront for Nxera's gut-targeting IBD program, adding to a portfolio anchored by Skyrizi and Rinvoq. endpoints.news/abbvie-bets-u…
Novo now expects flat 2026 sales, an upgrade from its prior forecast, as longtime CFO Karsten Munk Knudsen departs. endpoints.news/novo-forecast…
🎙️ Live tomorrow at 1:30 pm ET: What the midterms mean for biopharma, with @ArmstrongDrew, @maxonwifi and policy expert Nick Shipley. endpoints.news/post-hoc-live…
Pfizer's Albert Bourla doesn't expect Democratic gains in Congress to change the MFN deals, which run through the end of Trump's term. endpoints.news/bourla-expect…
